Roche presents updated clinical trial data for hemlibra

SWITZERLAND – Roche has released results for its haemophilia A therapy candidate, Hemlibra which confirm that its has a favorable safety profile. In the analysis, no new safety signals were identified with long-term Hemlibra treatment in adults and adolescents with haemophilia A having inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. STASEY study data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, held from 17-21 July 2021. Final analysis of the STASEY study included data…

Read More